NASDAQ:KRYS

Krystal Biotech Stock Predictions

Healthcare > Biotechnology

Buy KRYS

*Your capital is at risk

$301.82

+8.61 (+2.94%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

KRYS Prediction Chart

KRYS Predictions History

Latest community submissions for KRYS.

Predictor	Target Session	Target Price	Result	Direction	Accuracy
GoldenNugget Pro	May 7, 2019	$30.60 -4.90%	$32.18	X	95.10%
GoldenNugget Pro	May 6, 2019	$30.97 -1.89%	$31.57	X	98.11%
NameNotImportant Pro	May 3, 2019	$32.55 +3.76%	$31.37	X	96.24%
NameNotImportant Pro	Apr 24, 2019	$33.70 +1.94%	$33.06	X	98.06%
NameNotImportant Pro	Apr 23, 2019	$30.58 -9.39%	$33.75	X	90.61%
Shreemkaari	Oct 22, 2018	$16.55 -21.64%	$21.12	X	78.40%

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for KRYS with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT KRYSTAL BIOTECH INC

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by